Literature DB >> 1242874

Primary tumors of the small bowel.

T A Treadwell, R R White.   

Abstract

Primary tumors of the small bowel are uncommon, representing less than 6 per cent of all gastrointestinal tumors and less than 2 per cent of all malignant gastrointestinal tumors. This report concerns a twenty-five year survey of our clinical records from 1946 to 1971 which revealed 140 primary small bowel tumors, excluding periampullary tumors. Fifty-two of the neoplasms (37 per cent) were benign; eighty-eight (63 per cent) were malignant and included twenty-eight adenocarcinomas (31.8 per cent), twenty-four lymphosarcomas (27.3 per cent), nineteen carcinoids (21.6 per cent), and ten leiomyosarcomas (11.4 per cent). The average age at the time of diagnosis was 56.9 years for patients with benign tumors and 55.9 years for those with malignant tumors. The illusive and obscure nature of small bowel tumors is illustrated by the fact that 63.3 per cent of patients with benign lesions and 47.6 per cent of those with malignant lesions had symptoms for more than six months before the diagnosis was made. Bleeding was the most common present complaint in patients with benign neoplasms (52.9 per cent) whereas patients with malignant lesions more often had symptoms of obstruction (50.6 per cent). Most of the benign lesions were located proximally in the small bowel (duodenum, 34.6 per cent; ileum, 11.5 per cent), and most of the malignant lesions were located distally (duodenum, 17.0 per cent; ileum, 61.4 per cent). Treatment of patients with malignant lesions was radical excision whenever possible. Adjunctive radiation therapy was used for those with lymphoma. A second benign or malignant tumor occurred in 42.9 per cent of the patients with primary small bowel tumors. The average period of survival after diagnosis of a malignant small bowel tumor was 5.03 years: for patients with adenocarcinoma, 3.6 years; lymphosarcoma, 1.3 years; carcinoid, 6.8 years; and leiomyosarcoma, 8.3 years.

Entities:  

Mesh:

Year:  1975        PMID: 1242874     DOI: 10.1016/0002-9610(75)90435-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  9 in total

1.  Gastrointestinal smooth muscle tumors in children: report of three cases.

Authors:  A K Gupta; M Berry; D K Mitra
Journal:  Pediatr Radiol       Date:  1994

2.  Adenocarcinoma of small bowel in 12-year-old girl.

Authors:  J W Tankel; C S Galasko
Journal:  J R Soc Med       Date:  1984-08       Impact factor: 5.344

3.  Enteric adenoma and adenocarcinoma.

Authors:  M J Cooper; R C Williamson
Journal:  World J Surg       Date:  1985-12       Impact factor: 3.352

Review 4.  Intraductal papillary mucinous neoplasm originating from a jejunal heterotopic pancreas: report of a case.

Authors:  Hiroshi Okamoto; Fumiyoshi Fujishima; Kazuyuki Ishida; Ken Tsuchida; Takuya Shimizu; Hitoshi Goto; Akira Sato; Susumu Satomi; Hironobu Sasano
Journal:  Surg Today       Date:  2013-01-18       Impact factor: 2.549

5.  Small bowel tumors: clinical presentation, prognosis, and outcome in 33 patients in a tertiary care center.

Authors:  Mirna H Farhat; Ali I Shamseddine; Kassem A Barada
Journal:  J Oncol       Date:  2008-12-02       Impact factor: 4.375

6.  Primary small intestinal tumours: increased incidence of lymphoma and improved survival.

Authors:  C J O'Boyle; M J Kerin; K Feeley; H F Given
Journal:  Ann R Coll Surg Engl       Date:  1998-09       Impact factor: 1.891

7.  Small bowel tumours: yield of enteroscopy.

Authors:  B S Lewis; A Kornbluth; J D Waye
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

8.  Adenocarcinoma and lymphoma of the small intestine. Distribution and etiologic associations.

Authors:  R C Williamson; C E Welch; R A Malt
Journal:  Ann Surg       Date:  1983-02       Impact factor: 12.969

9.  Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.

Authors:  Sylvain Manfredi; Thimote Thiebot; Sebastien Henno; Ludivine Falize; Jean François Bretagne; Bernard Meunier
Journal:  J Gastrointest Surg       Date:  2009-07-08       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.